Experts from the FDA and CDC continue their discussion on tecovirimat, or TPOXX, for the treatment of monkeypox in infected individuals. In part two of this mini-series, experts answer physicians' questions about treatment for monkeypox. Guests include Adam Sherwat, MD, Deputy Director, Office of Infectious Disease at FDA’s Center for Drug Evaluation and Research; Brett W. Petersen, MD, MPH, Deputy Chief, Poxvirus and Rabies Branch, CDC’s Division of High-Consequence Pathogens and Pathology; and Timothy Wilkin, MD, MPH, Professor of Medicine and Assistant Dean for Clinical Research Compliance for Human Research Protections at Weill Cornell Medicine and TPOXX clinical trial lead.
📺 Follow the @americanmedicalassociation on YouTube:
[ Ссылка ]
🎥 Watch #AMAUpdate for the latest in health care news for physicians:
[ Ссылка ]
📝 Full transcripts of the show are available here:
[ Ссылка ]
📧 Subscribe to AMA Morning Rounds newsletter, with the news you need
every morning delivered to your inbox: [ Ссылка ]
🎧 Listen to our latest podcast episodes now: [ Ссылка ]
📲 Download AMA Connect for news, podcasts, video updates and learning in
one place: [ Ссылка ]
💬 Connect with the AMA on social media: [ Ссылка ]
![](https://s2.save4k.ru/pic/VzcSMlYFark/maxresdefault.jpg)